Goldman Sachs Upgrades St. Jude Medical (STJ) to Buy

Goldman Sachs upgraded St. Jude Medical (NYSE: STJ) from Neutral to Buy and raised their price target from $45 to $50, suggesting 29% upside.

"Share gains in core markets and entrance into new therapeutic categories should support accelerating organic revenue growth through 2015," the analyst said.

Dissipating headwinds should turn the focus back on longer-term product cycle, the analyst said. They see improving top-line outlook yielding upward EPS forecast revisions and subsequent P/E multiple expansion.

Goldman raised FY12 EPS from $3.49 to $3.51, FY13 from $3.71 to $3.79 and FY14 from $4.10 to $4.20.

For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.

Shares of St. Jude Medical closed at $38.88 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Needham Upgrades Netflix (NFLX) to Buy, 'on Rev Upside from Tech Stack'
• QuantumScape (QS) PT Lowered to $6 at Truist Securities
• Voestalpine AG (VOE:AV) (VLPNF) PT Lowered to EUR33 at Barclays